**Table S12. Sample size sensitivity analysis. Continuous data results**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Clinical outcome** | **Sub-group**  **(number of studies)** | **Sample size** | **Timepoint** | **Hedges's g** | **95% CI** | **p-value** | **I²** (%) | **τ²** |
| Cognition | **Objective cognition** |  | | | | | | |
| Cognitive change (n=13) | Follow-up and baseline | Collapsed | -0.192 | -0.285– -0.099 | <0.001 | 73.1 | 0.017 |
| Cognitive change (n=9) | Follow-up and baseline | ≤6 months | -0.158 | -0.258– -0.058 | 0.002 | 52.5 | 0.011 |
| Cognitive change (n=5) | Follow-up and baseline | >6–12 months | -0.052 | -0.254– 0.150 | 0.613 | 71.0 | 0.035 |
| Cognitive change (n=4) | Follow-up and baseline | >12 months | -0.154 | -0.302– -0.006 | 0.042 | 73.5 | 0.015 |
| Cognitive change (n=8) | Follow-up only | Collapsed | -0.185 | -0.258– -0.112 | <0.001 | 44.3 | 0.004 |
| Cognitive change (n=6) | Follow-up only | ≤6 months | -0.143 | -0.258– -0.029 | 0.014 | 58.1 | 0.011 |
| Cognitive change (n=4) | Follow-up only | >6–12 months | -0.102 | -0.316– 0.113 | 0.354 | 71.7 | 0.032 |
| Cognitive change (n=2) | Follow-up only | >12 months | -0.247 | -0.316– -0.177 | <0.001 | 0.0 | 0.000 |
| Cognitive performance (n=36) | Follow-up and baseline | Collapsed | -0.689 | -0.822– -0.555 | <0.001 | 94.7 | 0.141 |
| Cognitive performance (n=28) | Follow-up and baseline | ≤6 months | -0.657 | -0.810– -0.505 | <0.001 | 91.5 | 0.136 |
| Cognitive performance (n=17) | Follow-up and baseline | >6–12 months | -0.601 | -0.790– -0.411 | <0.001 | 88.2 | 0.127 |
| Cognitive performance (n=11) | Follow-up and baseline | >12 months | -0.794 | -1.096– -0.492 | <0.001 | 96.7 | 0.235 |
| Cognitive performance (n=30) | Follow-up only | Collapsed | -0.752 | -0.911– -0.593 | <0.001 | 95.3 | 0.168 |
| Cognitive performance (n=23) | Follow-up only | ≤6 months | -0.707 | -0.890– -0.524 | <0.001 | 92.6 | 0.163 |
| Cognitive performance (n=14) | Follow-up only | >6–12 months | -0.663 | -0.901– -0.424 | <0.001 | 88.9 | 0.169 |
| Cognitive performance (n=9) | Follow-up only | >12 months | -0.856 | -1.209– -0.503 | <0.001 | 97.2 | 0.263 |
| **Subjective cognition** |  | | | | | | |
| Cognitive performance (n=7) | Follow-up and baseline | Collapsed | -0.191 | -0.336– -0.046 | 0.010 | 72.6 | 0.025 |
| Cognitive performance (n=5) | Follow-up and baseline | ≤6 months | -0.254 | -0.405– -0.103 | 0.001 | 48.2 | 0.014 |
| Cognitive performance (n=5) | Follow-up only | Collapsed | -0.209 | -0.393– -0.026 | 0.026 | 80.1 | 0.032 |
| Cognitive performance (n=3) | Follow-up only | ≤6 months | -0.333 | -0.491– -0.174 | <0.001 | 29.0 | 0.007 |
| Functional outcome | Functional change (n=10) | Follow-up and baseline | Collapsed | -0.432 | -0.694– -0.170 | 0.001 | 87.3 | 0.143 |
| Functional change (n=7) | Follow-up and baseline | ≤6 months | -0.433 | -0.764– -0.102 | 0.010 | 90.3 | 0.172 |
| Functional change (n=2) | Follow-up and baseline | >12 months | -0.279 | -0.887– 0.329 | 0.368 | 76.7 | 0.149 |
| Functional change (n=7) | Follow-up only | Collapsed | -0.258 | -0.462– -0.054 | 0.013 | 71.2 | 0.047 |
| Functional change (n=5) | Follow-up only | ≤6 months | -0.165 | -0.367– 0.036 | 0.108 | 68.4 | 0.034 |
| Functional performance (n=37) | Follow-up and baseline | Collapsed | -0.616 | -0.827– -0.405 | <0.001 | 97.7 | 0.404 |
| Functional performance (n=30) | Follow-up and baseline | ≤6 months | -0.608 | -0.866– -0.349 | <0.001 | 97.6 | 0.502 |
| Functional performance (n=13) | Follow-up and baseline | >6–12 months | -0.581 | -0.892– -0.270 | <0.001 | 95.6 | 0.297 |
| Functional performance (n=7) | Follow-up and baseline | >12 months | -0.544 | -0.851– -0.237 | 0.001 | 92.2 | 0.144 |
| Functional performance (n=31) | Follow-up only | Collapsed | -0.644 | -0.895– -0.393 | <0.001 | 98.0 | 0.481 |
| Functional performance (n=25) | Follow-up only | ≤6 months | -0.624 | -0.940– -0.309 | <0.001 | 97.9 | 0.624 |
| Functional performance (n=12) | Follow-up only | >6–12 months | -0.607 | -0.951– -0.264 | 0.001 | 95.8 | 0.335 |
| Functional performance (n=6) | Follow-up only | >12 months | -0.617 | -0.964– -0.269 | 0.001 | 93.4 | 0.160 |
| Quality of life | Poor quality of life (n=22) | Follow-up and baseline | Collapsed | -0.443 | -0.563 to -0.323 | <0.001 | 93.6 | 0.068 |
| Poor quality of life (n=14) | Follow-up and baseline | ≤6 months | -0.331 | -0.465 to -0.196 | <0.001 | 88.8 | 0.051 |
| Poor quality of life (n=8) | Follow-up and baseline | >6–12 months | -0.419 | -0.613 to -0.225 | <0.001 | 89.5 | 0.062 |
| Poor quality of life (n=15) | Follow-up only | Collapsed | -0.549 | -0.718 to -0.381 | <0.001 | 95.5 | 0.094 |
| Poor quality of life (n=8) | Follow-up only | ≤6 months | -0.420 | -0.675 to -0.165 | 0.001 | 93.1 | 0.116 |
| Poor quality of life (n=6) | Follow-up only | >6–12 months | -0.493 | -0.729 to -0.257 | <0.001 | 89.6 | 0.067 |

**Footnote:** Data not presented when less than 2 studies available.Baseline sample sizes were used for 10 studies on cognition, 8 studies on functional outcomes, and 7 studies on quality-of-life outcomes due to the absence of follow-up sample sizes.

All studies in this analyses were continuous data.

For all other outcomes, follow-up sample sizes were used.

A single study could report multiple outcomes